Results 51 to 60 of about 169,757 (284)

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves, Arcaro, Asou, Bouscary, Bouscary, Bouscary, Bowles, Carroll, Carroll, DiPersio, Druker, Esmaeili-Mahani, Finan, Gandhi, Giese, Gilliland, Hirsch, Johnson, Jordan, Kahl, Khwaja, Khwaja, Ko, Konopleva, MacEwan, MacEwan, Niitsu, Pettitt, Pocock, Preudhomme, Recher, Ronnstrand, Rushworth, Solary, Ulrich, Wei, Wymann, Wymann   +37 more
core   +1 more source

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Journal of Clinical Oncology, 2014
PURPOSE More than half of patients with chronic-phase chronic myelogenous leukemia (CP-CML) in complete molecular response (CMR) experience molecular relapse after imatinib discontinuation.
P. Rousselot, A. Charbonnier, P. Cony-Makhoul, P. Agapé, F. Nicolini, B. Varet, M. Gardembas, G. Étienne, D. Réa, L. Roy, M. Escoffre-barbe, A. Guerci-Bresler, M. Tulliez, S. Prost, M. Spentchian, J. Cayuela, J. Reiffers, J. Chomel, A. Turhan, J. Guilhot, F. Guilhot, F. Mahon   +21 more
semanticscholar   +1 more source

Permanent Sensorineural Deafness in a Patient with Chronic Myelogenous Leukemia Secondary to Intracranial Hemorrhage

Case Reports in Hematology, 2013
A 52-year-old male presented with tinnitus and fullness in left ear for one day. Workup revealed a white blood cell count of 685×103/μL with marked increase in granulocyte series and myeloid precursors on peripheral smear.
Sakshi Kapur, Michael Wax, Levin Miles, Adnan Hussain   +3 more
doaj   +1 more source

Profiling of Metabolic Differences between Hematopoietic Stem Cells and Acute/Chronic Myeloid Leukemia

Metabolites, 2020
Although many studies have been conducted on leukemia, only a few have analyzed the metabolomic profiles of various leukemic cells. In this study, the metabolomes of THP-1, U937, KG-1 (acute myelogenous leukemia, AML), K562 (chronic myelogenous leukemia,
Byung Hoo Song, Su Young Son, Hyun Kyu Kim, Tae Won Ha, Jeong Suk Im, Aeli Ryu, Hyeji Jeon, Hee Yong Chung, Jae Sang Oh, Choong Hwan Lee, Man Ryul Lee   +10 more
doaj   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa   +53 more
core   +1 more source

Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells

Molecular Cancer, 2014
BackgroundRecent findings indicate that exosomes released from cancer cells contain microRNAs (miRNAs) that may be delivered to cells of tumor microenvironment.ResultsTo elucidate whether miRNAs secreted from chronic myelogenous leukemia cells (CML) are ...
S. Taverna, V. Amodeo, L. Saieva, A. Russo, M. Giallombardo, G. De Leo, R. Alessandro   +6 more
semanticscholar   +1 more source

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

Revista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moises M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles   +8 more
doaj   +1 more source

A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report

SAGE Open Medical Case Reports, 2018
Bosutinib is a BCR-ABL tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome–positive chronic myelogenous leukemia. We report a case of bosutinib-induced interstitial granulomatous drug reaction in a 50-year-old Caucasian female
Alexander B Aria, Leon Chen, Auris O Huen   +2 more
doaj   +1 more source

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
A Quintas-Cardama, A Quintas-Cardama, A Quintas-Cardama, AJ Tipping, AJ Tipping, B Zhang, C Akgul, C Bellodi, G Gurel, H de Lavallade, H Konig, HG Jorgensen, HM Kantarjian, J Kuroda, KJ Aichberger, L Legros, M Copland, M Copland, NB Heaney, R Chen, R Tang, RG Powell, RM Stone, S Chu, SM Graham, SV Sharma, T Kobayashi, Y Chen   +27 more
core   +1 more source

Targeting quiescent leukemic stem cells using second generation autophagy inhibitors [PDF]

, 2019
In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment induces autophagy that promotes survival and TKI-resistance in leukemic stem cells (LSCs).
A Hamilton, A Kuma, AS Corbin, B Ronan, B Zhang, B Zhang, BJ Druker, C Bellodi, D Mahalingam, DJ Klionsky, DT Vogl, E Weisberg, F Liu, G Karsli-Uzunbas, JD Mancias, JY Guo, JY Guo, M Karvela, M Komatsu, M Mortensen, M Schemionek, MR Rosenfeld, MR Warr, MT Rosenfeldt, N Mizushima, P Rousselot, Q McAfee, R Bago, R Rangwala, R Rangwala, S Brenner, S Kimura, S Koschmieder, SM Graham, T Holyoake, TL Holyoake, TL Holyoake, TT Ho, V Kirkin, VW Rebecca, WE Dowdle, XH Ma, Z Tothova   +42 more
core   +2 more sources